Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David N. Bolus is active.

Publication


Featured researches published by David N. Bolus.


Inorganica Chimica Acta | 1982

The interaction of substituted catechols with some binuclear copper(II) compounds

David N. Bolus; Gerald S. Vigee

Four dicopper(II) complexes were tested as catalysts for the air oxidation of several substituted o-diphenols. The oxidation reactions were followed by measuring the change in the optical spectra and by measuring the oxygen uptake. The oxidase activities decreased with a decrease in pH and increased for o-diphenols with good electron donating substituents in the para position. Because of their complexity, the oxidation products were not identified and characterized. Lack of characterized products prevented an analysis of the reaction mechanism.


Hpb | 2015

Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm

Rojymon Jacob; Falynn Turley; David T. Redden; Souheil Saddekni; Ahmed Kamel Abdel Aal; K.S. Keene; Eddy S. Yang; Jessica G. Zarzour; David N. Bolus; J. Kevin Smith; Stephen H. Gray; Jared A. White; Devin E. Eckhoff; Derek A. DuBay

OBJECTIVES The optimal locoregional treatment for non-resectable hepatocellular carcinoma (HCC) of ≥ 3 cm in diameter is unclear. Transarterial chemoembolization (TACE) is the initial intervention most commonly performed, but it rarely eradicates HCC. The purpose of this study was to measure survival in HCC patients treated with adjuvant stereotactic body radiotherapy (SBRT) following TACE. METHODS A retrospective study of patients with HCC of ≥ 3 cm was conducted. Outcomes in patients treated with TACE alone (n = 124) were compared with outcomes in those treated with TACE + SBRT (n = 37). RESULTS There were no significant baseline differences between the two groups. The pre-TACE mean number of tumours (P = 0.57), largest tumour size (P = 0.09) and total tumour diameter (P = 0.21) did not differ significantly between the groups. Necrosis of the HCC tumour, measured after the first TACE, did not differ between the groups (P = 0.69). Local recurrence was significantly decreased in the TACE + SBRT group (10.8%) in comparison with the TACE-only group (25.8%) (P = 0.04). After censoring for liver transplantation, overall survival was found to be significantly increased in the TACE + SBRT group compared with the TACE-only group (33 months and 20 months, respectively; P = 0.02). CONCLUSIONS This retrospective study suggests that in patients with HCC tumours of ≥ 3 cm, treatment with TACE + SBRT provides a survival advantage over treatment with only TACE. Confirmation of this observation requires that the concept be tested in a prospective, randomized clinical trial.


Radiology | 2011

Assessment of Adverse Reaction Rates during Gadoteridol-enhanced MR Imaging in 28 078 Patients

Desiree E. Morgan; J. Stephen Stephen Spann; Mark E. Lockhart; Beth Winningham; David N. Bolus

PURPOSE To determine adverse reaction rates in a tertiary care clinical setting after adoption of gadoteridol as the institutional routine magnetic resonance (MR) imaging contrast agent. MATERIALS AND METHODS With institutional review board approval, informed consent waiver, and HIPAA compliance, a prospective observational study of 28 078 patients who underwent intravenous gadoteridol-enhanced MR imaging from July 2007 to December 2009 was performed. Reactions were recorded by technologists who noted types of reactions, method of injection, and treatment. Reactions were classified as mild, moderate, or severe per American College of Radiology definitions. Comparisons of reaction rates with dose and method of injection were analyzed with the Fisher exact and χ(2) tests. RESULTS Overall reaction rate was 0.666% (187 patients), including 177 mild, six moderate, and four severe reactions. Treatment was given in 27 patients (14.4%). The most frequent reaction was nausea (and/or vomiting) in 149 patients (79.7% of patients with any adverse reaction, 0.530% of overall population). Method of injection did not affect reaction rate or severity. There was no difference in type or severity of reactions in comparison of patients receiving half the dose versus patients receiving the standard dose (P = .33-.75). CONCLUSION The observed adverse reaction rate to gadoteridol was lower than previously reported. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992. Rates of adverse reactions for this macrocyclic contrast agent are comparable to those published for linear gadolinium-based contrast agents.


Journal of Computer Assisted Tomography | 2016

White paper of the society of computed body tomography and magnetic resonance on dual-energy ct, part 2: Radiation dose and iodine sensitivity

W. Dennis Foley; William P. Shuman; Marilyn J. Siegel; Dushyant V. Sahani; Daniel T. Boll; David N. Bolus; Carlo N. De Cecco; Ravi K. Kaza; Desiree E. Morgan; U. Joseph Schoepf; Terri J. Vrtiska; Benjamin M. Yeh; Lincoln L. Berland

Abstract This is the second of a series of 4 white papers that represent Expert Consensus Documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its task force on dual-energy computed tomography. This paper, part 2, addresses radiation dose and iodine sensitivity in dual-energy computed tomography.


Journal of Computer Assisted Tomography | 2016

White paper of the society of computed body tomography and magnetic resonance on dual-energy ct, part 1: Technology and terminology

Marilyn J. Siegel; Ravi K. Kaza; David N. Bolus; Daniel T. Boll; Neil M. Rofsky; Carlo N. De Cecco; W. Dennis Foley; Desiree E. Morgan; U. Joseph Schoepf; Dushyant V. Sahani; William P. Shuman; Terri J. Vrtiska; Benjamin M. Yeh; Lincoln L. Berland

This is the first of a series of 4 white papers that represent Expert Consensus Documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its task force on dual-energy computed tomography (DECT). This article, part 1, describes the fundamentals of the physical basis for DECT and the technology of DECT and proposes uniform nomenclature to account for differences in proprietary terms among manufacturers.


Journal of Computer Assisted Tomography | 2013

Dual-energy computed tomographic scanners: principles, comparisons, and contrasts.

David N. Bolus

Abstract The underlying principles of dual-energy computed tomography are reviewed, with comparison and contrast of the primary dual-energy computed tomographic scanners that are currently in use. Practical clinical implications of the differences in hardware, software, and imaging processing implementations are discussed, noting the rationale for convergence of technology and terminology.


Journal of Computer Assisted Tomography | 2017

White Paper of the Society of Computed Body Tomography and Magnetic Resonance on Dual-Energy CT, Part 4: Abdominal and Pelvic Applications.

Carlo N. De Cecco; Daniel T. Boll; David N. Bolus; W. Dennis Foley; Ravi K. Kaza; Desiree E. Morgan; Neil M. Rofsky; Dushyant V. Sahani; U. Joseph Schoepf; William P. Shuman; Marilyn J. Siegel; Terri J. Vrtiska; Benjamin M. Yeh; Lincoln L. Berland

This is the fourth of a series of 4 white papers that represent expert consensus documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its task force on dual-energy computed tomography. This article, part 4, discusses DECT for abdominal and pelvic applications and, at the end of each, will offer our consensus opinions on the current clinical utility of the application and opportunities for further research.


Hpb | 2014

Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma

Jared A. White; David T. Redden; Mary K. Bryant; David P. Dorn; Souheil Saddekni; Ahmed Kamel Abdel Aal; Jessica G. Zarzour; David N. Bolus; J. Kevin Smith; Stephen H. Gray; Devin E. Eckhoff; Derek A. DuBay

OBJECTIVES Repeat transarterial chemoembolization (TACE) is a common intervention performed for hepatocellular carcinoma (HCC). The aim of this study was to identify predictors of the need for repeat TACE. METHODS Between 2008 and 2012, data on patient and tumour variables were collected for 262 patients treated with a first TACE procedure for HCC. The decision to perform repeat TACE procedures was made at the completion of the first TACE or after follow-up imaging demonstrated the subtotal treatment of HCC tumours. RESULTS Repeat TACE was performed in 67 of 262 (25.6%) patients. Necrosis of HCC, measured after the first TACE, was lower in patients who subsequently received repeat TACE (P = 0.042). On multivariable analysis, total tumour diameter of >5 cm [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.45-5.25; P = 0.002] and increasing age (OR 1.04/year, 95% CI 1.00-1.07; P = 0.030) were predictive of the need for repeat TACE. Measures of liver function and TACE approach (selective versus non-selective) were not predictive of repeat TACE. Median survival did not differ significantly between patients who did (median survival: 21.1 months) and did not (median survival: 26.1 months) receive a repeat TACE procedure (P = 0.574). CONCLUSIONS The requirement for repeat TACE is associated with older age, increased HCC tumour burden and subtotal TACE-induced HCC necrosis. Importantly, repeat TACE was not associated with reduced survival.


Journal of Computer Assisted Tomography | 2017

White paper of the society of computed body tomography and magnetic resonance on dual-energy CT, part 3: Vascular, cardiac, pulmonary, and musculoskeletal applications

Carlo N. De Cecco; U. Joseph Schoepf; Lynne S. Steinbach; Daniel T. Boll; W. Dennis Foley; Ravi K. Kaza; David N. Bolus; Desiree E. Morgan; Dushyant V. Sahani; William P. Shuman; Marilyn J. Siegel; Terri J. Vrtiska; Benjamin M. Yeh; Lincoln L. Berland

This is the third of a series of 4 white papers that represent Expert Consensus Documents developed by the Society of Computed Body Tomography and Magnetic Resonance through its Task Force on dual-energy computed tomography. This paper, part 3, describes computed tomography angiography and thoracic, cardiac, vascular, and musculoskeletal clinical applications. At the end of the discussion of each application category (vascular, cardiac, pulmonary, and musculoskeletal), we present our consensus opinions on the current clinical utility of the application and opportunities for further research.


Journal of Ultrasound in Medicine | 2016

Effect of Anticoagulation Medication on the Thyroid Fine-Needle Aspiration Pathologic Diagnostic Sufficiency Rate

S. LeeAnn Wilson Denham; Aimen Ismail; David N. Bolus; Mark E. Lockhart

This study examined whether ultrasound‐guided thyroid fine‐needle aspiration (FNA) biopsy performed on patients taking anticoagulation medication results in a greater number of nondiagnostic pathologic samples due to a higher propensity to bleed, and thus fill the needle with blood rather than cellular material, compared to patients not taking anticoagulation medication.

Collaboration


Dive into the David N. Bolus's collaboration.

Top Co-Authors

Avatar

Desiree E. Morgan

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Lincoln L. Berland

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlo N. De Cecco

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jared A. White

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Marilyn J. Siegel

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen H. Gray

University of Alabama at Birmingham

View shared research outputs
Researchain Logo
Decentralizing Knowledge